BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Focused on Advancing NurOwn into Phase 3b ENDURANCE Trial BrainStorm ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that causes the gradual loss of motor neurons in the brain and spinal cord, leading to muscle weakness, paralysis, and ...

SineuGene Therapeutics Co., Ltd. ("SineuGene"), clinical-stage biotechnology company that mainly focuses on gene therapies for neurological disorders, announced today that China's National Medical ...

In the beginning, not even Hynek Wichterle's postdoc thought his idea to slow the progression of amyotrophic lateral ...

Long-term exposure to sulfur dioxide, an air pollutant generated by the burning of fossil fuels, increases the risk of ALS, a ...

A new discovery about mutations in a gene that causes ALS may allow researchers to design targeted therapies, a study found.

A patient with amyotrophic lateral sclerosis (ALS) has become the first person in the world to control an iPad entirely by ...

Answer ALS, in collaboration with ALS Therapy Development Institute (ALS TDI) and Augie's Quest, today announced plans to ...

After the loss of his mother to ALS, a Kansas City man gave two Chiefs fans who are ALS patients the tour of a lifetime.

The ALS treatment market, valued at USD 791.90 Million in 2024, is forecasted to grow at a CAGR of 5.40% from 2025 to 2034. Rising ALS prevalence, demand for treatments, and advancing research propel ...

The amyotrophic lateral sclerosis (ALS) treatment market was valued at USD 791.90 Million in 2024 and is projected to expand at a compound annual growth rate (CAGR) of 5.40% from 2025 to 2034.